(March 6, 2026) –This week, the American Hospital Association sent a letter urging the Health Resources and Services Administration to stop Novo Nordisk's 340B claims data submission policy from taking effect on April 1. The letter followed Novo Nordisk's March 2 notice to 340B covered entities that, effective April 1, 2026, it will require all CE types to submit claims level data for pharmacy and medical dispenses for all 340B dispenses, including in-house and contract pharmacy dispenses. Novo Nordisk's policy is identical to Eli Lilly's 340B claims data submission policy, which was issued in late January.
AHA's communication urges HRSA to take immediate enforcement action, including the use of civil monetary penalties, against both Lilly and Novo to halt their new policies. The letter also asks that if HRSA chooses not to take such action, it must inform 340B hospitals and other stakeholders and explain why these new policies are lawful under the 340B statute.
KHA staff will continue to monitor this activity and keep our members informed about new developments.
--Karen Braman